Agenus Inc. (AGEN)
Nasdaq · Healthcare · Biotechnology
$8.73+4.43%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $394M
- P/E (trailing)
- 3.5
- 52-week range
- $2.71 – $10.31
- 52-week change
- +101.45%
- EPS (trailing)
- $2.53
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $114M (+10.38%)
- Net income
- −$3.1M
- Operating margin
- −17.7%
- Diluted EPS
- $0.00
- Free cash flow
- −$77.2M
From the company’s annual report on SEC EDGAR.
About Agenus Inc.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884.
Headquarters: Lexington, United States · 81 employees · agenusbio.com